scholarly journals Clinical Efficacy of Unani Drug in the Management of Tabkheer-I-Meda (Gastroesophageal Reflux Disease)

AYUSHDHARA ◽  
2021 ◽  
pp. 3405-3411
Author(s):  
Najmus Sehar ◽  
Khan Mohammad Nafees ◽  
Salam Mahboob ◽  
Naeem Mohd ◽  
Akhtar Jamal
Keyword(s):  
Reflux Disease ◽  
Epigastric Pain ◽  
Acid Reflux ◽  
Mucosal Damage ◽  
Modern Medicine ◽  
Burning Sensation ◽  
Base Line ◽  
Esophageal Reflux ◽  
Gastric Contents ◽  
Associated Symptoms

Tabkheer-i-meda has been described as reflux of acid from stomach in the Unani classical literatures. This disease is characterized by various symptoms like indigestion, pain in abdomen, suppression of thrust, burning sensation in the epigastrium, anorexia, nausea and acid reflux etc. In modern medicine, Gastro-esophageal Reflux Disease (GERD) is defined as symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus or beyond, into the oral cavity (including larynx) or lungs. The objective of the present study was to evaluate the efficacy of Safoof-i-Tabkheer on the patients suffering with associated symptoms of Tabkheer-i-Meda (Gastro-esophageal Reflux Disease). Patients were advised orally 5grams of Safoof-i-Tabkheer with water twice daily after the meal. It was observed that after the treatment, all associated symptoms of Tabkheer-i-Meda/ GRED including retrosternal burning, epigastric pain acidic brash and anorexia were significantly (p<0.05) reduced. The percentage reduction in retrosternal burning, acidicbrash, epigastric pain and anorexia were 53.89%, 51.56%, 48.53% and 40.65% respectively as compared to base line. No adverse effect of drug was found. Highly significant improvements (p<0.001, paired t test) in all associated symptom of the disease suggest that the results are really due to the therapy. On the ground of above observation, it can be concluded that the Unani pharamacopieal formulation ‘Safoof-i-Tabkheer’ is very effective and safe in the treatment of Tabkheer-i-Meda.

scholarly journals GASTRO-ESOPHAGEAL REFLUX DISEASE AND ITS IMPACT ON TRACHEO-ESOPHAGEAL SPEAKING VALVE REHABILITATION AFTER TOTAL LARYNGECTOMY

2019 ◽  
Vol 6 (1) ◽  
pp. 24-29
Author(s):  
A. Nicolaescu ◽  
Ș. Berteșteanu ◽  
R. Grigore ◽  
B. Popescu ◽  
R. Hainăroșie ◽  
...  
Keyword(s):  
Reflux Disease ◽  
Total Laryngectomy ◽  
English Language ◽  
Proteolytic Enzymes ◽  
Acid Reflux ◽  
Oral Feeding ◽  
Esophageal Fistula ◽  
Esophageal Reflux ◽  
Speaking Valve ◽  
Speech Rehabilitation

Gastro-esophageal reflux disease (GERD) is a pathological entity in which the mixture of gastric contents (with low pH because of the high content of HCl acid) and biliary juice (rich in proteolytic enzymes like pepsin and trypsin) causes lesions on the mucosa lining the esophagus. A higher prevalence of GERD was discovered in patients who had a total laryngectomy. Concerning laryngectomies with tracheo-esophageal speaking valves, it has been demonstrated that GERD is an independent risk factor for failure of this method of speech rehabilitation. The authors performed an analysis of English language articles found following a search of the major medical scientific databases (NCBI®, EMBASE®, Cochrane®) containing the following keyword string: vocal prosthesis, total laryngectomy, GERD, acid reflux, tracheo-esophageal fistula, failure. Studies showed that exposure to the protelolytic enzymes from the reflux juice increases the diameter of the tracheo-esophageal fistula and permits local granulation tissue to form. Progressively, the increasing fistula diameter leads to complications ranging from microaspiration of liquids and saliva to speaking valve expulsion or ingestion and temporary incapacity of oral feeding. Medical therapy in the postoperative period as well as long-term (6 months or more) correction of GERD (PPI therapy, H2 blockers, prokinetics) is also demonstrated to reduce the complication rate in this category of patients. GERD has a high prevalence in the total laryngectomy population of patients and it has multiple etiologic factors. In patients with tracheoesophageal vocal prostheses, GERD causes an increase in the fistula diameter – with important consequences that affect the patient's quality of life - his ability to phonate and his ability to swallow. These complications come with added costs because of the need to more frequently change the vocal prostheses with ones increasing in diameter, as well as multiple hospitalizations (even surgery to recalibrate or close the tracheo-esophageal fistula). Recognizing and treating this condition therefore decreases the risk of complications following vocal prosthesis speech rehabilitation.

The Effects of Itopride on Acid and Non-Acid Reflux in Patients With Erosive Gastro Esophageal Reflux Disease (GERD).

2011 ◽  
Vol 140 (5) ◽  
pp. S-582
Author(s):  
Jose M. Remes Troche ◽  
Alberto Aviles-Calderon ◽  
Maura Torres-Aguilera ◽  
Antonio Ramos-De la Medina ◽  
Victoria A. Jimenez-Garcia ◽  
...  
Keyword(s):  
Reflux Disease ◽  
Acid Reflux ◽  
Esophageal Reflux

S1903 Dominant Epigastric Pain May Be a Symptom of Gastro-Esophageal Reflux Disease (GERD)

2009 ◽  
Vol 136 (5) ◽  
pp. A-288-A-289
Author(s):  
Siavosh Nasseri-Moghaddam ◽  
Anahita Ghorbani ◽  
Hadi Razjouyan ◽  
Azadeh Mofid ◽  
Mansoureh Mamarabadi ◽  
...  
Keyword(s):  
Reflux Disease ◽  
Epigastric Pain ◽  
Esophageal Reflux

719 REDUCED MEAN NOCTURNAL BASELINE IMPEDANCE AIDS DIAGNOSIS OF GASTRO-ESOPHAGEAL REFLUX DISEASE AND LARYNGOPHARYNGEAL REFLUX DISEASE

2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Jin-soo Park ◽  
Hans Van der Wall ◽  
Gregory Falk
Keyword(s):  
Reflux Disease ◽  
Laryngopharyngeal Reflux ◽  
Acid Reflux ◽  
Acid Exposure ◽  
Esophageal Reflux ◽  
Clinical Diagnoses ◽  
Laryngopharyngeal Reflux Disease ◽  
Acid Exposure Time ◽  
Esophageal Impedance ◽  
Aids Diagnosis

Abstract   Laryngopharyngeal reflux disease (LPR) and gastro-esophageal reflux disease (GERD) occur due to acidic gastric refluxate causing symptoms. Baseline esophageal impedance has been shown to be reduced with prolonged acid exposure. Mean nocturnal baseline impedance (MNBI) is a novel measure that has shown promise in GERD but has not been evaluated in LPR. This study aimed to assess the role of MNBI in LPR and GERD patients. Methods Off-therapy impedance-pH tracings were blindly reviewed for 187 patients previously prospectively allocated clinical diagnoses of LPR (n = 105) or GERD (n = 82). Conventional impedance-pH measures and MNBI were analysed for the two groups. Results MNBI was significantly lower in the distal esophagus in GERD patients compared with LPR (1679 ± 914 vs. 2109 ± 863; p = 0.001). Similarly, in the proximal esophagus, MNBI was lower in GERD than LPR (2289 ± 579 vs. 2541 ± 471; p = 0.001). In the pharynx, MNBI was similar between the two groups (2116 ± 699 vs. 2133 ± 770; p = 0.878). Distal acid exposure time (AET) and the number of distal acid reflux episodes negatively correlated with distal esophageal MNBI (r = −0.195; p = 0.007) and (r = −0.330; p &lt; 0.001) respectively. Conclusion Baseline impedance was reduced in both LPR and GERD at both distal and proximal esophageal measurements, and more severely reduced in GERD. Baseline impedance is strongly and inversely related to acid exposure in the esophagus. Pharyngeal MNBI was not reduced or different between groups. Distal and proximal esophageal MNBI may be useful in diagnosis of LPR as well as GERD.

scholarly journals Cancer Prevention in Patients with GERD and Barrett’s Esophagus—Medicine

2021 ◽  
Vol 1 (1) ◽  
pp. 50-62
Author(s):  
Carmelo Scarpignato ◽  
David H. Wang
Keyword(s):  
Risk Factors ◽  
Reactive Oxygen Species ◽  
Cell Proliferation ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Acid Reflux ◽  
Oxygen Species ◽  
Esophageal Reflux ◽  
Early Disease ◽  
Chemopreventive Agents

Gastro-esophageal reflux disease (GERD) and Barrett’s esophagus are risk factors for esophageal adenocarcinoma (EAC). Chemoprevention is an attractive strategy, more effective than identifying early disease. Since acid reflux can lead to increased cell proliferation, decreased apoptosis, production of reactive oxygen species, DNA damage, and esophageal production of proinflammatory and pro-proliferative cytokines, proton pump inhibitors (PPIs) alone, or in combination with COX-inhibition, are the most suitable chemopreventive agents. Other compounds (statins, metformin, and selected nutraceuticals) cannot currently be recommended. Data are strong enough to warrant PPI treatment of virtually all patients with Barrett’s esophagus, although the best regimen has not yet been defined.

Sign in / Sign up

Export Citation Format

Share Document